Prism Medico & Pharmacy Ltd

Prism Medico & Pharmacy has announced its financial results for the quarter ending December 2024, revealing stability in performance with no changes in its score over the past three months. The company continues to navigate the healthcare sector's complexities, maintaining consistent operational metrics amid industry dynamics.

Prism Medico & Pharmacy has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. Despite this, the company has shown some resilience by outperforming its sector. However, it continues to trade below key moving averages, indicating ongoing challenges.

Prism Medico & Pharmacy has reached a new 52-week low, reflecting a significant decline in its stock price, which has dropped 47.32% over the past year. The company has underperformed compared to the broader market, with its stock trading below key moving averages, indicating ongoing challenges.

Prism Medico & Pharmacy has reached a new 52-week low, reflecting a significant decline in its stock price, which has dropped 47.32% over the past year. The company has underperformed compared to the broader market, with its stock trading below key moving averages, indicating ongoing challenges.

Prism Medico & Pharmacy has reached a new 52-week low, reflecting a significant decline in its stock price, which has dropped 47.32% over the past year. The company has underperformed compared to the broader market, with its stock trading below key moving averages, indicating ongoing challenges.

Prism Medico & Pharmacy has faced significant volatility, hitting a new 52-week low and experiencing an eight-day decline totaling 24.4%. The company's stock has dropped 46.76% over the past year, underperforming its sector and trading below multiple moving averages, reflecting ongoing challenges in the healthcare market.

Prism Medico & Pharmacy has reached a new 52-week low, despite a short-term gain that contrasts with its significant year-long decline. The stock is underperforming compared to broader market indices and is trading below multiple moving averages, reflecting ongoing challenges in the competitive healthcare sector.

Prism Medico & Pharmacy has hit a new 52-week low, marking a significant decline over the past six days. Despite outperforming its sector today, the stock has seen a substantial one-year drop. Currently, it trades below multiple moving averages, indicating a continued downward trend.

Prism Medico & Pharmacy has reached a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and is trading below key moving averages, with a notable 43.31% drop over the past year, contrasting with broader market gains.

Prism Medico & Pharmacy has hit a new 52-week low, with its stock price at Rs. 19.05. The company has experienced a significant decline over the past year, underperforming its sector and trading below multiple moving averages, indicating a sustained downward trend.

Prism Medico & Pharmacy, a microcap healthcare services company, has reported flat performance for the quarter ended June 2024. However, the company's Profit After Tax has increased to Rs 0.03 crore for the nine-month period, showing a positive trend. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.

Prism Medico & Pharmacy, a microcap healthcare services company, has seen a significant drop in its stock price, hitting a 52-week low of Rs.21.7 on May 14, 2024. This has resulted in a Strong Sell rating from MarketsMOJO, with the stock underperforming the sector by -3.56%. The company's stock has been on a consecutive decline for the last two days and is currently trading below its moving averages. In comparison to the Sensex, Prism Medico's one-year performance has been negative, indicating potential challenges for the company in the current market. Investors are advised to conduct their own research before investing.

Prism Medico & Pharmacy, a microcap healthcare services company, has been on a downward trend for the past three days, with a decrease of -12.71% in returns. On March 26, the stock hit a 52-week low of Rs 22.05, showing high volatility and trading below its moving averages. With a negative performance of -19.26% in the past year, investors may want to consider selling their shares in the company.

Prism Medico & Pharmacy, a microcap healthcare services company, has reported positive financial results for the quarter ending December 2023. The company's operating profit, profit before tax, and profit after tax have all shown an upward trend, with the highest figures in the last five quarters. The company's earnings per share have also increased, leading to a 'Sell' call from MarketsMOJO.

Prism Medico & Pharmacy, a microcap healthcare services company, reported a 44.44% growth in standalone net profit and a 30.00% growth in operating profit for the quarter ended September 2023. However, net sales remained flat and operating profit margin saw a decline. MarketsMOJO has given a 'Strong Sell' call for the company's stock.